Telomerase inhibition may contribute to accelerated mitochondrial aging induced by anti-retroviral HIV treatment

Medical Hypotheses

Volumn 81, Issue 2, 2013, Pages 285-287

  Bollmann, F M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; MITOCHONDRIAL TOXICITY; MITOCHONDRION; PREMATURE AGING;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; MITOCHONDRIA; MODELS, THEORETICAL; TELOMERASE;

EID: 84880041210     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.04.028     Document Type: Article

References (47)

1. Desquilbet L., Jacobson L.P., Fried L.P., et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007, 62:1279-1286.
2. Blanco F., San Román J., Vispo E., et al. Management of metabolic complications and cardiovascular risk in HIV-infected patients. AIDS Rev 2010, 12:231-241.
3. Valcour V., Shikuma C., Shiramizu B., et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology 2004, 63:822-827.
4. Côté H.C., Brumme Z.L., Craib K.J., et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002, 346:811-820.
5. Maagaard A., Holberg-Petersen M., Kollberg G., Oldfors A., Sandvik L., Bruun J.N. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 2006, 11:601-608.
6. Lim S.E., Copeland W.C. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001, 276:23616-23623.
7. Trifunovic A., Wredenberg A., Falkenberg M., et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429:417-423.
8. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003, 2:812-822.
9. Apostolova N., Blas-García A., Esplugues J.V. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends Pharmacol Sci 2011, 32:715-725.
10. Payne B.A., Wilson I.J., Hateley C.A., et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011, 43:806-810.
11. Coller H.A., Bodyak N.D., Khrapko K. Frequent intracellular clonal expansions of somatic mtDNA mutations: significance and mechanisms. Ann NY Acad Sci 2002, 959:434-447.
12. Harrington L., Zhou W., McPhail T., et al. Human telomerase contains evolutionary conserved catalytic and structural subunits. Genes Dev 1997, 11:3109-3115.
13. Bollmann F.M. The many faces of telomerase: emerging extratelomeric effects. BioEssays 2008, 30:728-732.
14. Santos J.H., Meyer J.N., Skorvaga M., Annab L.A., Van Houten B. Mitochondrial hTERT exacerbates free radical-mediated mtDNA damage. Aging Cell 2004, 6:399-411.
15. Santos J.H., Meyer J.N., Van Houten B. Mitochondrial localization of hTERT as a determinant for hydrogen peroxide-induced mtDNA damage and apoptosis. Hum Mol Genet 2006, 15:1757-1768.
16. Ahmed S., Passos J.F., Birket M.J., et al. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci 2008, 121:1046-1053.
17. Haendeler J., Dröse S., Büchner N., et al. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. Arterioscler Thromb Vasc Biol 2009, 6:929-935.
18. Sharma N.K., Reyes A., Green P., et al. Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. Nucleic Acids Res 2011, 40:712-725.
19. Kovalenko O.A., Caron M.J., Ulema P., et al. A mutant telomerase defective in nuclear-cytoplasmic shuttling fails to immortalize cells and is associated with mitochondrial dysfunction. Aging Cell 2010, 9:203-219.
20. Ling X., Wen L., Zhou Y. Role of mitochondrial translocation of telomerase in hepatocellular carcinoma cells with multidrug resistance. Int J Med Sci 2012, 9:545-554.
21. Sahin E., Colla S., Liesa M., et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470:359-365.
22. Strahl C., Blackburn E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996, 16:53-65.
23. Yegorov Y.E., Chernov D.N., Akimov S.S., Bolsheva N.L., Krayevsky A.A., Zelenin A.V. Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett 1996, 389:115-118.
24. Melana S.M., Holland J.F., Pogo B.G. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythymidine. Clin Cancer Res 1998, 4:693-696.
25. Gomez D.E., Tejera A.M., Olivero O.A. Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment. Biochem Biophys Res Commun 1998, 246:107-110.
26. Multani A.S., Furlong C., Pathak S. Reduction of telomeric signals in murine melanoma and breast cancer cell lines treated with 3'-azido-2'-3'-dideoxythymidine. Int J Oncol 1998, 13:923-925.
27. Murakami J., Nagai N., Shigemasa K., Ohama K. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer 1999, 35:1027-1034.
28. Beltz L., Moran R., Elsawy O., Sadler J., Jurgenson J. The effects of telomerase inhibitors on lymphocyte function. Anticancer Res 1999, 19:3205-3211.
29. Falchetti A., Franchi A., Bordi C., et al. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res 2005, 20:410-418.
30. Fang J.L., Beland F.A. Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci 2009, 111:120-130.
31. Strahl C., Blackburn E.H. The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res 1994, 22:893-900.
32. Olivero O.A., Anderson L.M., Diwan B.A., et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997, 89:1602-1608.
33. Coté H.C.F., Soudeyns H., Thorne A., et al. Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: shorter telomeres with uncontrolled HIV viremia. PLoS ONE 2012, 7:e39266.
34. Jeng K.S., Sheen I.S., Jeng W.J. Azidothymidine treatment of hepatocellular carcinoma in rats: an in vivo study of telomerase inhibition. Hepatogastroenterology 2011, 58:2091-2096.
35. Gomez D.E., Armando R.G., Alonso D.F. AZT as a telomerase inhibitor. Front Oncol 2012, 2:113.
36. Hájek M., Matulová N., Votruba I., Holý A., Tloust'ová E. Inhibition of human telomerase by diphosphates of acylic nucleoside phosphonates. Biochem Pharmacol 2005, 70:894-900.
37. Hukezalie K.R., Thumati N.R., Cote H.C., Wong J.M. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. PLoS ONE 2012, 7:e47505.
38. Leeansyah E., Cameron P.U., Solomon A., et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis 2013, 207:1157-1165.
39. Bachor C., Bachor O.A., Boukamp P. Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions. J Cancer Res Clin Oncol 1999, 125:453-460.
40. Yasumoto S., Kunimura C., Kikuchi K., et al. Telomerase activity in normal human epithelial cells. Oncogene 1996, 13:433-439.
41. Liu J., Baykal A., Fung K.M., et al. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int J Oncol 2004, 24:879-884.
42. Nagao K., Ohyashiki J.H., Ohyashiki K., et al. Expression of hTERT mRNA in a mortal liver cell line during S phase without detectable telomerase activity. Int J Mol Med 2005, 15:683-688.
43. Masutomi K., Yu E.Y., Khurts S., et al. Telomerase maintains telomere structure in normal human cells. Cell 2003, 114:241-253.
44. Wolthers K.C., Otto S.A., Wisman G.B., et al. Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection. Blood 1999, 93:1011-1019.
45. Tucker V., Jenkins J., Gilmour J., et al. T-cell telomere length maintained in HIV-infected long-term survivors. HIV Med 2000, 1:116-122.
46. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011, 2011:480-486.
47. Singhapol C., Pal D., Czapiewski R., et al. Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis. PLoS ONE 2013, 8:e52989.